SCHEMBL3310183

SCHEMBL3310183

COCCN(C)C(=O)c1cc(OC)c(C(C)(C)C)cc1-c1ccc[nH]c1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.37
TMEM97 Q5BJF2 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
LRRK2 Q5S007 4/20 0.36
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HTR2C P28335 1/20 0.35
CDK4 P11802 1/20 0.34
CCND1 P24385 1/20 0.34
CYP3A4 P08684 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
MAP4K4 O95819 1/20 0.33
RBP4 P02753 2/20 0.33
CD274 Q9NZQ7 1/20 0.33
CYP1A1 P04798 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3316087 0.87 MAP4K1 (0.38) HPGDCYP3A4CD274CYP1A1
SCHEMBL3311118 0.85 CYP3A4 (0.35) KDM4ECDK4CCND1CYP3A4NPC1
SCHEMBL3310672 0.83 HSD17B1 (0.41) HPGDCYP3A4ROCK2ROCK1HSD17B1
SCHEMBL3312829 0.83 MAPT (0.39) KDM4EHPGDHSD17B10CYP3A4ROCK2
SCHEMBL2350724 0.81 NAPRT (0.43) KDM4EHPGDCYP3A4CYP1A1
SCHEMBL2362083 0.80 PLK1 (0.38) KDM4EHPGDHSD17B10CYP3A4CD274
SCHEMBL2349673 0.80 CYP1A1 (0.37) HPGDCYP3A4NPC1RAB9ACD274
SCHEMBL2354432 0.79 KDM4E (0.40) KDM4EHPGDCYP3A4NPC1RAB9A
SCHEMBL3313129 0.77 CYP3A4 (0.36) KDM4ECYP3A4CD274CYP1A1
SCHEMBL3310488 0.77 CYP3A4 (0.39) KDM4EHPGDCYP3A4NPC1CYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232271-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-07-31 US claimed
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-05-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, EIF2AK2, POLR2B KCNH2 3404/4885TMEM97 2373/4885SIGMAR1 471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.